Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Oral Bivalent Norovirus Vaccine in Lactating Females and Their Infants
NCT07254728Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Viral Vector Vaccines, Drug Delivery Systems, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VXA-GI.1.NN and VXA-G2.4-NS in norovirus infection (3 arms), sponsored by Vaxart, Inc. Primary endpoints: Number of Participants With Any Solicited Symptoms of Reactogenicity at 1 week, Number of Participants With Unsolicited Treatment-emergent Adverse Events at 4 weeks and 2 more. Started Oct 2023; status: completed.
02
Drugs
VXA-GI.1.NNVXA-G2.4-NS
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT07254728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254728.